All In Biotech

Drug Trial Radar · NCT06957418

Alzheimer's Tau Platform: Master Protocol

The Alzheimer's Disease Tau Platform Clinical Trial

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Jul 6, 2026

Primary completion

Aug 31, 2028

Study completion Aug 31, 2028

Sponsor

Lead sponsor
Paul S. AisenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA); University of California, San Francisco; Massachusetts General Hospital; Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium
First posted
May 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. This platform trial allows for the simultaneous testing of multiple tau therapies under a shared master protocol. This means that multiple investigational products will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. The main questions the platform trial aims to answer are: * Does a tau-directed therapy, alone or in combination with donanemab, reduce tau buildup in the brain compared to donanemab alone? * Does a tau-directed therapy, alone or in combination with donanemab, slow disease progression based on brain imaging, fluid biomarkers, and measures of memory and thinking? Participants will: * Be randomized to a treatment regimens, each containing different tau therapies. The exact number of treatment regimens that will active at the time of screening will change over time. * Receive donanemab or placebo for 6 months, followed by 24 months of tau therapy alone or in combination with donanemab. * Undergo regular cognitive testing, brain scans (MRI/PET), and biomarker assessments over 30 months Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to one of three arms: (1) tau therapy alone, (2) a combination of donanemab and tau therapy, or (3) donanemab alone. New regimens will be continuously added as new investigational products become available. The Alzheimer's Tau Platform Trial will enroll additional participants as each new regimen becomes available. ATP will launch with one regimen: Regimen A: AADvac1. In the future, Regimen B ("Tau2") will launch with a second tau directed therapy.

Conditions

  • Preclinical Alzheimer's Disease
  • Alzheimer Disease
  • Prodromal Alzheimer's Disease

Interventions

  • AADvac1Drug

    AADvac1 tau directed therapy

  • Tau2Drug

    Tau2 directed therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of brain tau deposition as measured by tau positron emission tomography (PET)Time frame: 0, 6, 18 and 30 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Banner Alzheimer's Institute

    Phoenix, Arizona · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Kentucky Sanders Brown Center on Aging

    Lexington, Kentucky · Recruiting

  • Brigham and Women's Hospital Center for Alzheimer Research and Treatment

    Boston, Massachusetts · Recruiting

  • Butler Hospital Memory and Aging Program

    Providence, Rhode Island · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Harborview Medical Center, University of Washington

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.